FindTrial
Sign In

A Study to Evaluate Efficacy of Selected Homoeopathic Medicines in Prevention of COVID-19

A Pragmatic, Placebo-controlled, Parallel Groups, Randomised Clinical Trial to Assess the Efficacy of Homoeopathic Medicine(s) in the Prevention of COVID-19 in a High Risk / Exposed Population

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028280
Enrollment
18000
Registered
2020-10-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Homoeopathic Medicine: Subjects will receive either of the three medicines (Arsenic album 30, Camphora 1M, Bryonia alba 30) or placebo. Two doses each of 4 pills of size 30 to be admini
thereafter two doses once a day every week for the entire study period. Control Intervention1: Placebo: Subjects will receive either of the three medicines (Arsenic album 30, Camphora 1M, Bryonia alba

Sponsors

Directorate of AYUSH Govt of NCT of Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Asymptomatic sybjects (no symptoms of fever, cough, breathlessness in the previous 7 days). Living in a containment zones and family/community/social clusters of positive cases. Subjects of 18 to 60 years of age.

Exclusion criteria

Exclusion criteria: Has taken any of the medication Arsenic album 30, Camphora 1M, Bryonia alba 30 during last one month. Tested positive for COVID-19 with RT-PCR/Ag Test. Any member of household tested positive for COVID-19 with RT-PCR/Ag Test. Individuals with uncontrolled, unstable comorbidities. Malignant, HIV and Immunocompromised patients. Patients taking Corticosteroids or on chemotherapy. Pregnant Women and Lactating Mothers. Patients with Septicemia, UTI or any other infection.

Design outcomes

Primary

MeasureTime frame
Proportion of individuals in each of the groupsâ?? that develop COVID-19, confirmed with the RT-PCR/Ag test. Average duration in which individuals turned positive/developed symptoms.Timepoint: Baseline; thereafter every seventh day—

Secondary

MeasureTime frame
Proportion of individuals reporting symptoms of influenza like illness or well-established symptoms of COVID-19. Change in the Symptom severity. Average duration until disease recovery after testing positive/day of appearance of symptoms. Change in ICU Admission Rate. Change in the Mortality Rate. Change in the immune status using Immune Status Questionnaire.Timepoint: Every seventh day—

Countries

India

Contacts

Public ContactDr Meeta Gupta

Directorate of AYUSH (Homoeopathic Wing), Govt. of NCT of Delhi

drmeetagupta@gmail.com9811727072

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026